Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of new sensitive biomarkers for the <i>in vivo</i> response to interferon‐β treatment in multiple sclerosis using DNA‐array evaluation

22 Jun 2009

Abstract excerpt

OBJECTIVE: Neutralizing antibodies (NAbs) occur in a proportion of multiple sclerosis (MS) patients treated with interferon (IFN)-beta. NAbs impair the effect of treatment. The biological effect of IFN-beta can be measured as the induction of the myxovirus resistance protein A (MxA) molecule. However, other markers could be more sensitive for evaluating the response to IFN-beta. We used DNA array analysis to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Sclerosis Research Studies
Share to Systemic Lupus Erythematosus Research
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19558503
DOI: 10.1111/j.1468-1331.2009.02716.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of new sensitive biomarkers for the <i>in vivo</i> response to interferon‐β treatment in multiple sclerosis using DNA‐array evaluationPMID 19558503Read ↗

Search for Specific Biomarkers of IFNβ Bioactivity in Patients with Multiple SclerosisSemantic proximity Read ↗

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1Semantic proximity Read ↗

Time course transcriptomics of IFNB1b drug therapy in multiple sclerosisSemantic proximity Read ↗

Multiplex analysis of expression of three IFNβ-induced genes in antibody-positive MS patientsSemantic proximity Read ↗

Gene expression analysis of interferon-β treatment in multiple sclerosisSemantic proximity Read ↗

Long-Term Genome-Wide Blood RNA Expression Profiles Yield Novel Molecular Response Candidates for IFN-β-1b Treatment in Relapsing Remitting MSSemantic proximity Read ↗

Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genesSemantic proximity Read ↗

Novel interferon-β-induced gene expression in peripheral blood cellsSemantic proximity Read ↗

Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevanceSemantic proximity Read ↗

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between PatientsSemantic proximity Read ↗

HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.Semantic proximity Read ↗

Gene Expression Profiling of the Response to Interferon Beta in Epstein-Barr-Transformed and Primary B Cells of Patients with Multiple SclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.